IL-RF-IDEAS
13.7.2021 15:02:14 CEST | Business Wire | Press release
rf IDEAS, a leading manufacturer of credential readers for authentication and logical access, is proud to announce that it is the recipient of the 2021 HP Partner Award for Partner Agility.
Presented at the virtually held HP Developer Partner Conference 2021, this award recognizes rf IDEAS for its role in helping HP land a successful worldwide deployment deal, featuring readers with Bluetooth® Low Energy technology, for its development agility, and for managing the changes and challenges over the past year. “This award represents the great relationship we have built with HP,” said David Cottingham, president of rf IDEAS. “We were able to take secure authentication to the next level by deploying a solution that combines mobile credentials and secure physical employee badges. Through a difficult year, we have been able to execute on tough delivery timelines and offer continued support to HP and their customers long after the product leaves our warehouse.”
For the last 13 years, rf IDEAS and HP partnered together to provide leading authentication technology for HP’s Secure Print solutions for many top enterprise companies in multiple verticals around the world. During this time, rf IDEAS has built a robust supply chain to support HP in multiple routes to market such as direct MPS or indirect channel through worldwide distributors.
“The pandemic caused many new technical and logistical hurdles to overcome to deliver a highly complex and customized solution. Being able to adapt to an ever-changing environment in a positive, productive way requires real partnership, flexibility and a commitment to win,” said Paul Birkett, leader of HP’s Commercial Software Solutions for its print business. “rf IDEAS responsiveness to HP’s rapidly evolving customer needs is what made them stand out. rf IDEAS was instrumental in our work with this critical customer, and without the work of this partner, we would not have won a global multimillion-dollar Managed Print Services Deal.”
This is the fifth time HP has awarded to rf IDEAS for various achievements including Customer Focus in 2020, Partner Sales Excellence in 2017, Partner Collaboration in Excellence in 2016 and Partner in Excellence in 2014.
Learn more about rf IDEAS Secure Print solutions (link: https://www.rfideas.com/solutions/secure-print-management ).
About rf IDEAS
rf IDEAS, Inc. is a leader in logical access solutions for healthcare, manufacturing, government, education and enterprise. The company’s WAVE ID® readers (formerly pcProx®) are trusted by users across the globe and backed by strong partnerships with leading identity access management providers. rf IDEAS readers enable innovative solutions for single sign-on, secure printing, attendance tracking and mobile authentication while supporting nearly all credentials worldwide. For more information, visit www.rfIDEAS.com .
rf IDEAS® is a registered trademark of rf IDEAS, Inc. All other trademarks, service marks and product or service names are property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005095/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom